Recro Pharma Inc. (NASDAQ:REPH) has earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the firm. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $21.75.

Several research analysts recently commented on REPH shares. Janney Montgomery Scott started coverage on Recro Pharma in a research report on Monday, August 29th. They issued a “buy” rating and a $21.00 target price for the company. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research report on Wednesday, October 19th. Brean Capital started coverage on Recro Pharma in a research report on Monday, October 3rd. They issued a “buy” rating and a $21.00 target price for the company. Roth Capital started coverage on Recro Pharma in a research report on Friday, September 16th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Aegis started coverage on Recro Pharma in a research report on Monday, November 14th. They issued a “buy” rating and a $21.00 target price for the company.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC raised its position in Recro Pharma by 81.0% in the second quarter. Stonepine Capital Management LLC now owns 428,670 shares of the specialty pharmaceutical company’s stock valued at $3,408,000 after buying an additional 191,796 shares in the last quarter. Granite Point Capital Management L.P. bought a new position in Recro Pharma during the third quarter valued at about $636,000. Acadian Asset Management LLC bought a new position in Recro Pharma during the third quarter valued at about $140,000. Northern Trust Corp bought a new position in Recro Pharma during the third quarter valued at about $128,000. Finally, BlackRock Institutional Trust Company N.A. raised its position in Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares in the last quarter. Hedge funds and other institutional investors own 36.63% of the company’s stock.

Shares of Recro Pharma (NASDAQ:REPH) opened at 8.57 on Monday. The firm’s market capitalization is $84.58 million. Recro Pharma has a one year low of $5.59 and a one year high of $12.50. The firm has a 50-day moving average of $7.74 and a 200-day moving average of $8.24.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

5 Day Chart for NASDAQ:REPH

Receive News & Stock Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related stocks with our FREE daily email newsletter.